PMC5404710_01
Capillary glucose (mg/dL) monitoring profile pre- and post-procedure: before therapy with diazoxide, with 5% dextrose continuous infusion at night and frequent oral feeding during daytime (D2); medical therapy with diazoxide associated with continuous nocturnal dextrose infusion and frequent oral feeding during daytime (D4-D8) and 5 months post EUS ethanol ablation therapy without any adjuvant medical therapy (M5).
edmcr-2017-160145-g001.jpg
PMC5404710_01_edmcr-2017-160145-g001.jpg
fig1
Imaging investigation. (A) Abdominal CT scan before EUS ethanol ablation therapy revealed a nodular hypervascular lesion with 12 mm size. (B) EUS-guided ethanol ablation therapy: a total of 0.6 mL of 95% ethanol was injected into the lesion by a transgastric approach; 3/4 of the nodular lesion changed from hypoechoic to hyperechoic appearance after ethanol injection. (C) Post-procedure CT scan showing a residual pancreatic nodular lesion currently measuring 6 mm and less enhancement.
edmcr-2017-160145-g002.jpg
PMC5404710_01_edmcr-2017-160145-g002.jpg
fig2